Table 2 High levels of Annexin-A2 (ANXA2) in serum as a potential biomarker for cancers

Hepatocellular carcinoma

70

<  0.001

Patients (n = 50, median, 69.6 ng/ml)

Healthy individuals (n = 20, median, 9.5 ng/ml)

[25]

Hepatocellular carcinoma (early stage)

70

<  0.01

Patients (n = 50, median, 130 ng/ml)

Healthy individuals (n = 20, median, 17 ng/ml)

[26]

Gastric cancer

93

<  0.001

Patients (n = 63, median, 211.0 ng/ml)

Healthy individuals (n = 30, median, 120.5 ng/ml)

[27]

Lung cancer

85

<  0.01

Patients (n = 42)

Healthy individuals (n = 43)

[28]

Oral squamous cell carcinoma

284

<  0.01

Patients (n = 126, median, 27.1 ng/ml)

Healthy individuals (n = 158, median, 15 ng/ml)

[29]